<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

2 min read

Future Growth? Q222 Extremities Market Recap

By Lisa Mahan on 9/15/22 9:30 AM

A variety of conditions decelerated Extremities Market growth, but new product introductions should accelerate future growth 

Companies across the Extremities space reported a variety of conditions decelerating growth in Q222, including supply chain challenges, elective procedure cancellations due to COVID, facility staffing issues and reduced demand for trauma-related devices. WW Extremities Market growth slowed sequentially in Q222 compared to Q122. The US Extremities Market also saw slowing sequential growth. Moving forward, SmartTRAK  expects Extremities market growth to accelerate as headwinds lessen and new product introductions boost revenue.
 

Among the many topics covered in detail in our comprehensive Q222 Extremities Market Recap* are:

Continue Reading
3 min read

Onlay vs Inlay Glenoids: An Interview with John Uribe, MD

By Lisa Mahan on 9/13/22 9:30 AM

John Uribe, MD, discusses inset glenoid technology and the future of shoulder replacement

John Uribe, MD, discusses his most recent research and experience with inset glenoids and how inset glenoids could influence the practice of shoulder replacement surgery. Dr. Uribe is a dual board-certified orthopedic surgeon with Baptist Health Group South Florida specializing in sports medicine, arthroscopic surgery and minimally invasive surgical procedures for degenerative knee, shoulder and elbow conditions. He is also the Chair of the Herbert Wertheim College of Medicine, Coral Gables, FL and the team physician for the Florida Panthers hockey team and the Miami Dolphins football team.

Dr. Uribe authored a study published in JSES International reporting results from 39 patients with advanced shoulder arthritis having anatomic shoulder replacement with the OVOMotion Shoulder Arthroplasty System from Anika, a stemless shoulder with an inlay glenoid component. The study demonstrated that treatment with inlay total shoulder arthroplasty resulted in significant functional improvement, pain relief and patient satisfaction at a mean follow-up of 41 months.

To find out more, including Dr. Uribe’s thoughts on the benefits of inlay glenoids vs onlay; the potential acceptance of inlay technology; trends such as the shift to reverse shoulders, site-of-care; and what’s next, click on the video below to listen to the recorded interview (17:36 min). A link to download a complete transcript of the interview is also provided below.

Topics: Orthopedics
Continue Reading
2 min read

Positive YoY Growth Despite Stronger Headwinds: Q222 Total Joints Market Recap

By Lisa Mahan on 9/7/22 9:30 AM

Despite stronger headwinds from slowing elective procedures, supply chain challenges and unfavorable foreign exchange rates, most total joint companies saw positive growth in Q222.

The WW Total Joints Market grew in Q222 despite slowing sequential growth compared to Q122’s growth. A slowdown in elective procedures late in the quarter along with continued supply chain challenges and the effect of foreign exchange rates resulted in stronger headwinds. SmartTRAK notes that several companies reported the carryover of these headwinds into Q3 that could dampen market recovery through year-end.

Among the many topics covered in detail in our comprehensive Q222 Total Joints Market Recap* are:

Continue Reading
3 min read

A Mixed Bag of Ups & Downs: Q122 CAS Ortho Recap

By Shelly Caruso on 8/19/22 9:30 AM

Q122 proved to be a mixed-bag of ups and downs with supply chain issues and Covid surges having varying impacts on market leaders’ performance amidst a strong wave of enabling tech product launches.

The Q122 WW CAS Ortho Market was down according to SmartTRAK Financial Dashboard. Stryker* remained the market leader, followed by Zimmer Biomet* and Smith & Nephew*. For detailed Q122 revenues and shares by company in the US, EU and ROW, see the SmartTRAK CAS Ortho Financial Dashboard.

Among the many topics covered in detail in our comprehensive Q122 CAS Ortho Market Recap* are:

Continue Reading
2 min read

A Solid Recovery: Q122 Spine Market Recap

By Courtney Sheedy on 8/11/22 9:37 AM

Q122’s year-over-year growth in the WW Spine market shows normalized, nominal growth for this quarter, which should continue to improve over the course of the remaining year.

The US Spine Hardware market saw double-digit growth versus Q121, showing solid recovery gains from the same period prior year, which seemed to be riddled with ongoing volatility. Segment over segment within the spine market, we’re back to seeing growth in the areas that had been predicable growth segments prior to COVID-19. Although healthcare as a whole continues to rebuild, and staffing remains a challenge, many regions didn’t experience as negative an impact on the Spine market for Q122 as was predicted by many.

Among the many topics covered in detail in our comprehensive Q122 Spine Market Recap* are:

Continue Reading
2 min read

New Spine Enabling Technologies: Q122 CAS Spine Market Recap

By Shelly Caruso on 8/5/22 12:15 PM

Although revenues still show signs of COVID-19 impact, robotic procedures and implant pull-through accelerate, and companies continue roll out new spine enabling technology and strategize how to maximize the remainder of 2022.

The Q122 WW CAS Spine Market was up year-over-year according to SmartTRAK Financial DashboardMedtronic* (MDT) remained the market leader with 59.5% share, followed by Globus* (GMED) and other enabling tech competitors, including Stryker* (SYK) and Brainlab*

Among the many topics covered in detail in our comprehensive Q122 CAS Spine Market Recap* are:

Continue Reading
2 min read

Healthy Growth w/ Mixed Results: Q122 Trauma Market Recap

By Natasha Weeks on 7/28/22 9:30 AM

Despite mixed results from Trauma players, the segment experienced healthy growth as mergers and acquisitions were plentiful and regulatory clearances show promise of future new product introductions.

Continue Reading
2 min read

Alternative Posterior Fixation: An Interview with Rick Simmons at ISASS 2022

By Courtney Sheedy on 6/28/22 9:30 AM

Spinal Elements provides an in-depth look at the Company’s novel Karma Fixation System and what’s next for the technology at ISASS 2022

Spinal Elements Chief Marketing Officer Rick Simmons provides SmartTRAK an indepth look at the Company’s Karma Fixation System, a low-profile alternative to traditional pedicle screw technology, at the International Society of the Advancement for Spinal Surgery (ISASS) 2022 Annual Conference held June 1-4 in the Bahamas. Karma implants consist of a high-performance polymer, enabling an almost completely radiolucent approach to stabilizing the lumbar spine, as an adjunct to fusion and are designed to engage more predictably strong cortical bone. Click on the following video to find out more and see a demonstration of the current technology (7:00 min).

Continue Reading
2 min read

New Product Offerings in a Busy Quarter: Q122 Extremities Market Recap

By Lisa Mahan on 6/24/22 9:27 AM

The return of elective procedure volumes, new product offerings and a busy first quarter of acquisitions all supported healthy growth for the Extremities Market

While growth drivers varied for specific companies in Q122, the return of elective procedure volumes helped drive double-digit growth for several market players. Stryker*, the Extremities Market leader, benefited from the return of elective procedures in the US. Its US Foot & Ankle and Upper Extremities business segments contributed to the Company’s US Trauma & Extremities growth during the quarter. Stryker also noted during its earnings call that ...

Among the many topics covered in detail in our comprehensive Q122 Extremities Market Recap* are:

Continue Reading
2 min read

Soft Tissue Fixation Rebounds: Q122 Market Recap

By Andy Knapik on 6/22/22 11:10 AM

Soft Tissue Fixation Rebounds in Q122

After a slow end to 2021, Soft Tissue Fixation bounced back with procedure volumes rebounding in the first quarter of 2022. With 2021 being a year of ups and downs due to the COVID pandemic, staffing shortages and supply chain issues, the start of 2022 looked to be no different. However, even though the quarter started off a bit sluggish, it picked up steam quickly and ended on a positive note with worldwide Soft Tissue Fixation revenues up +7.5% over Q121.

Among the many topics covered in detail in our comprehensive Q122 Soft Tissue Fixation Market Recap* are:

Continue Reading

    Follow Us on Social Media

    Recent Articles